Okami Medical Raises $45 Million and Appoints New CEO to Support Expansion Plans

Okami Medical has closed an oversubscribed $45 million financing round, bringing in new lead investor Gilde Healthcare alongside continued support from Vensana Capital and U.S. Venture Partners. The California-based company develops devices for vascular embolization and plans to use the funding to expand its commercial presence and progress clinical programs focused on peripheral vessel occlusion.

The company said the investment will also support ongoing development of its device portfolio, including technologies aimed at improving procedural options for patients with vascular disease. Alongside the new funding, Okami announced leadership changes intended to strengthen its strategic direction as it scales operations.

Drew Hykes, former CEO of Inari Medical, has been appointed president and CEO. Bill Hoffman will serve as chairman of the board. Commenting on his appointment, Hykes said, “I’m honored to join the Okami team and have been deeply impressed by the clinical performance and versatility of the LOBO vascular occluder across a wide range of anatomies.” He added that he looks forward to advancing the company’s commercial expansion and innovation pipeline.

As part of the financing, Gilde Healthcare’s Geoff Pardo and Susana Amorim have joined the board of directors. Pardo said Gilde has followed the company’s progress closely. “We have been impressed by the strength of its technology and the scale of its market opportunity,” he said. He noted the firm’s prior collaboration with Hykes at Inari and expressed optimism about Okami’s potential to address unmet clinical needs.